|23rd November 2020||Advisors Llc Perceptive||500,000||Open or private purchase||$12.85||$6,425,000.00|
|27th October 2020||Advisors Llc Perceptive||3,000,000||Open or private purchase||$10.00||$30,000,000.00|
|21st October 2020||Advisors Llc Perceptive||43,195||Open or private purchase||$10.09||$435,837.55|
|20th October 2020||Advisors Llc Perceptive||114,100||Open or private purchase||$10.00||$1,141,000.00|
|1st October 2020||Augustine Lawlor||5,014||Grant/award etc.||$0.00|
|22nd September 2020||Advisors Llc Perceptive||1,644,785||Conversion of derivative||$0.00|
|22nd September 2020||Advisors Llc Perceptive||1,058,824||Open or private purchase||$17.00||$18,000,008.00|
|15th September 2020||Advisors Llc Perceptive||2,911,764||Open or private purchase||$4.25||$12,374,997.00|
|14th September 2020||Advisors Llc Perceptive||400,000||Open or private purchase||$40.00||$16,000,000.00|
|14th September 2020||Advisors Llc Perceptive||1,800,000||Open or private purchase||$11.00||$19,800,000.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01 and TRX518.